SERUM LEVELS OF HEMOPOIETIC AND ANGIOGENESIS GROWTH FACTORS (IL-5, IL-7, IL-9, FGF-β, G-CSF, VEGF AND PDGF) IN WOMEN WITH UTERINE MYOMA

Uterine leiomyomas are common benign tumors developing from smooth muscle tissues, often leading to infertility and recurrent abortions. Pregnancy and development of uterine fibroids are characterized by an unusual rate of myometrium growth, hyperproduction of extracellular matrix and increased expression of numerous growth factor receptors. The purpose of this study was to determine concentrations of some key growth factors (IL-5, IL-7, IL-9, FGF-β, G-CSF, VEGF and PDGF) in blood serum of women with uterine myoma. Concentrations of the 27 cytokines were determined using a Bio Rad kit (USA) – Bio-Plex Pro™. Human Cytokine 27-plex Assay by means of flow-through fluorometry at the Bio-Plex 200 double-beam laser analyzer. Thirty-six patients with verified uterine myoma were followed up, being later subject to operative treatment (laparoscopic myomectomy). The results of this study showed a trend to decreased amounts of some hematopoiesis and angiogenesis growth factors, e.g., IL-9 and FGF, in blood serum of women with uterine myoma. Сoncentrations of IL-5, IL-7, and G-CSF proved to be significantly decreased if compared to serum contents of European healthy women. The most significant decrease was registered for pro-angiogenic factors, such as VEGF and PDGF. Their serum concentration in women with leiomyoma was reduced, respectively, 3- and 6-fold against controls. The decreased G-CSF concentration was not only quite significant, as compared to healthy women, but showed significant correlations with changes of such factors as IL-5, IL-7 and IL-9, with correlation quotients of, resp., 0.723, 0.637, and 0.504, respectively. One may conclude that, in spite of literature data on significantly increased contents of the mentioned growth factors in tissues of myometrium and growing uterine leiomyoma, our data show that the concentrations of these regulatory proteins in blood serum are decreased to some extent in this clinical condition.

1. Konenkov V.I., Klimontov V.V., Chernykh V.V., Tyan N.V. Angiogenesis in proliferative diabetic retinopathy: perspectives of anti‑VEGF therapy (review of literature). Oftalmokhirurgiya = Fyodorov Journal of Ophthalmic Surgery, 2013, no. 4, pp. 111-115.(In Russ.)

2. Arita S., Kikkawa F., Kajiyama H., Shibata K., Kawai M., Mizuno K., Nagasaka T., Ino K., Nomura S. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.Int. J. Gynecol. Cancer, 2005, Vol. 15, no. 2, pp. 329-336.

3. Becher B., Tugues S., Greter M. GM‑CSF: from growth factor to central mediator of tissue inflammation. Immunity, 2016, Vol. 45, no. 5, pp. 963-973.

4. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res. C Embryo Today, 2003, Vol. 69, no. 4, pp. 272-285.

5. Ciarmela P., Bloise E., Gray P.C., Carrarelli P., Islam M.S., de Pascalis F., Severi F.M., Vale W., Castellucci M., Petraglia F. Activin‑A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid. J. Clin. Endocrinol. Metab., 2011, Vol. 96, no. 3, pp. 755-765.

6. Ciarmela P., Islam Md. S., Reis F.M., Gray P. C., Bloise E., Petraglia F., Vale W., Castellucci M. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum. Reprod. Update, 2011, Vol. 17, no. 6, pp. 772-790.

7. Gao J., Zhao L., Liu L., Yang Y., Guo B., Zhu B. Disrupted fibroblastic reticular cells and interleukin-7 expression in tumor draining lymph nodes. Oncol. Lett., 2017, Vol. 14, no. 3, pp. 2954-2960.

8. Hong T., Shimada Y., Uchida S., Itami A., Li Z., Ding Y., Kaganoi J., Komoto I., Sakurai T., Imamura M. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int. J. Mol. Med., 2001, Vol. 8, no. 2, pp. 141-148.

9. Itoh N., Ohta H., Nakayama Y., Konishi M. Roles of FGF signals in heart development, health, and disease. Front. Cell Dev. Biol., 2016, Vol. 4, p. 110.

10. Joseph D.S., Malik M., Nurudeen S., Catherino W.H. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta‑3. Fertil. Steril., 2010, Vol. 93, no. 5, pp. 1500-1508.

11. Kaplan M.H., Hufford M.M., Olson M.R. The development and in vivo function of T helper 9 cells.Nat. Rev. Immunol., 2015, Vol. 15, no. 5, pp. 295-307.

12. Liang M., Wang H., Zhang Y., Lu S., Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol. Ther., 2006, Vol. 5, no. 1, pp. 28-33.

13. McKay M.M., Morrison D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene, 2007, Vol. 26, no. 22, pp. 3113-3121.

14. Mesquita F.S., Dyer S.N., Heinrich D.A., Bulun S.E., Marsh E.E., Nowak R.A. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol. Reprod., 2010, Vol. 82, no. 2, pp. 341-351.

15. Moore A.B., Yu L., Swartz C.D., Zheng X., Wang L., Castro L., Kissling G.E., Walmer D.K., Robboy S.J., Dixon D. Human uterine leiomyoma‑derived fibroblasts stimulate uterine leiomyoma cell proliferation and collagen type I production, and activate RTKs and TGF beta receptor signaling in coculture.Cell Commun. Signal, 2010, Vol. 8, p. 10.

16. Nguyen V., Mendelsohn A., Larrick J.W. Interleukin‑7 and Immunosenescence.J. Immunol. Res., 2017, 4807853.doi: 10.1155/2017/4807853.

17. Sanci M., Dikis C., Inan S., Turkoz E., Dicle N., Ispahi C. Immunolocalization of VEGF, VEGF receptors, EGF‑R and Ki‑67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem., 2011, Vol. 113, no. 3, pp. 317-325.

18. Schollaert K.L., Stephens M.R., Gray J.K., Fulkerson P.C. Generation of eosinophils from cryopreserved murine bone marrow cells. PLoS ONE, 2014, Vol. 9, no. 12, e116141.doi: 10.1371/journal.pone.0116141.

19. Taniguchi Y., Morita I., Kubota T., Murota S., Aso T. Human uterine myometrial smooth muscle cell proliferation and vascular endothelial growth‑factor production in response to platelet‑derived growth factor. J. Endocrinol., 2001, Vol. 169, no. 1, pp. 79-86.

20. Vang R., Medeiros L.J., Samoszuk M., Deavers M.T. Uterine leiomyomas with Eosinophils: a clinicopathologic study of 3 cases. Int. J. Gynecol. Pathol., 2001, Vol. 20, no. 3, pp. 239-243.

21. Vempati P., Popel A.S., Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev., 2014, Vol. 25, no. 1, pp. 1-19.

22. Wegienka G., Baird D.D., Cooper T., Woodcroft K.J., Havstad S. Cytokine patterns differ seasonally between women with and without uterine leiomyomata. Am. J. Reprod. Immunol., 2013, Vol. 70, no. 4, pp. 327-335.

23. Wolanska M., Bankowska‑Guszczyn E., Jaworski S. Fibroblast growth factor gene expression in uterine leiomyomas. Ginekol. Pol., 2008, Vol. 79, no. 8, pp. 555-559.